⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

Official Title: An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors

Study ID: NCT02516813

Study Description

Brief Summary: MSC2490484A or M3814 is an investigational drug that is being evaluated for the treatment of subjects with locally advanced tumors. The main purposes of this study are to determine the safety, the tolerability and the efficacy of MSC2490484A in combination with radiotherapy and in combination with chemoradiotherapy (Radiotherapy + cisplatin).

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Research site, Fresno, California, United States

Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States

University of Miami Miller School of Medicine, Miami, Florida, United States

Research site, Billings, Montana, United States

Montefiore Medical Center PRIME, Bronx, New York, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Research site, Houston, Texas, United States

Research site, Tacoma, Washington, United States

Research site, Leuven, , Belgium

Rigshospitalet - PARENT, Copenhagen, , Denmark

Herlev Hospital - PARENT, Herlev, , Denmark

Research site, Freiburg, Baden Wuerttemberg, Germany

Charite Research Organisation GmbH - Phase - I Unit of Hematology and Oncology, Berlin, , Germany

Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, , Germany

Universitaetsklinikum Essen - Westdeutsches Tumorzentrum, Essen, , Germany

Universitaetsklinikum Heidelberg - RadioOnkologie und Strahlentherapie, Heidelberg, , Germany

Universitaetsklinikum Schleswig-Holstein - Campus Kiel - Klinik für diagnostische Radiologie, Kiel, , Germany

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz - Klinik und Poliklinik fuer Radiologie, Mainz, , Germany

Klinikum Mannheim GmbH Universitaetsklinikum - Parent, Mannheim, , Germany

Universitaetsklinikum Tuebingen - Medizinische Klinik I, Tuebingen, , Germany

Research site, Amsterdam, , Netherlands

Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, , Netherlands

Research site, Oslo, , Norway

Karolinska universitetssjukhuset - Solna - Radiumhemmet (onkologi), Solna, , Sweden

Universitaetsspital Zuerich - Parent, Zuerich, , Switzerland

Contact Details

Name: Medical Responsible

Affiliation: Merck KGaA, Darmstadt, Germany

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: